Relypsa Obtains $70,000,000 Series B Funding
-
Feed Type
-
Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=85cd9eb8-1139-4df2-9957-272cdbefa9d8&Preview=1 -
Date
9/13/2010 -
Company Name
Relypsa -
Mailing Address
5301 Patrick Henry Drive Santa Clara, CA 95054 -
Company Description
Relypsa, Inc. is a biopharmaceutical company leading the discovery and development of new non-absorbed polymeric drugs for important applications in renal and cardiovascular disease. The company’s most advanced therapeutic programs include a novel potassium binder for treatment of hyperkalemia, known as ILY-105, as well as a novel sodium binder, ILY102, for the potential treatment of congestive heart failure. Relypsa is dedicated to discover additional product candidates through use of its proprietary polymer platform. -
Website
http://www.relypsa.com -
Transaction Type
Venture Equity -
Transaction Amount
$70,000,000 -
Transaction Round
Series B -
Proceeds Purposes
Proceeds from the financing will support the advancement of Relypsa’s lead compound, RLY5016, through pivotal clinical studies. -
M&A Terms
-
Venture Investor
New Leaf Venture Partners -
Venture Investor
5AM Ventures -
Venture Investor
OrbiMed -
Venture Investor
Delphi Ventures
